D

Dogma Therapeutics

10 employees

Dogma is developing oral PCSK9 inhibitors to treat high cholesterol and cardiovascular disease. https://www.dogmatherapeutics.com/

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Pharmaceutical

Date founded

2017

Funding rounds raised

Total raised

$3.5M

from 3 investors over 3 rounds

D

Dogma Therapeutics raised $3.5M on April 1, 2017

Investors: Viva BioInnovator, JMCR Partners and Viva Ventures Biotech Fund

FAQ